1. |
1 Benson AB 3rd, Abrams TA, Ben-Josef E,
et al
. NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
J Natl Compr Canc Netw
, 2009, 7(4): 350-391.
|
2. |
2 Parikh P, Malhotra H, Jelic S; ESMO Guidelines Working Group.Hepatocellular carcinoma: ESMO Clinical Recommendation for diagnosis,treatment and follow-up.
Ann Oncol
, 2008, 19 Suppl 2: ii27-28.
|
3. |
3 Poon D, Anderson BO, Chen LT,
et al
. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.
Lancet Oncol
, 2009, 10(11): 1111-1118.
|
4. |
4 Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma.
Hepatology
, 2005, 42(5): 1208-1236.
|
5. |
5 Cammà C, Schepis F, Orlando A,
et al
. Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials.
Radiology
, 2002, 224(1): 47-54.
|
6. |
6 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.
Hepatology
, 2003, 37(2): 429-442.
|
7. |
7 Llovet JM, Real MI, Montana X,
et al
. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Lancet
, 2002, 359(9319): 1734-1739.
|
8. |
8 Lo CM, Ngan H, Tso WK,
et al
. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.
Hepatology
, 2002, 35(5): 1164-1171.
|
9. |
9 Marelli L, Stigliano R, Triantos C,
et al
. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.
Cardiovasc Intervent Radiol
, 2007, 30(1): 6-25.
|
10. |
10 Matsui O, Kadoya M, Yoshikawa J,
et al
. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization.
Radiology
, 1993, 188(1): 79-83.
|
11. |
11 Nishimine K, Uchida H, Matsuo N,
et al
. Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results.
Cancer Chemother Pharmacol
, 1994, 33 Suppl: S60-68.
|
12. |
13 Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis.
Hepatogastroenterology
, 2001, 48(37): 20-24.
|
13. |
14 Schoppmeyer K, Weis S, Mössner J,
et al
. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.
Cochrane Database Syst Rev
, 2009, 8(3): CD006745.
|
14. |
16 Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma.
Cochrane Database Syst Rev
, 2004, (2): CD003046.
|
15. |
17 Cho YK, Kim JK, Kim MY,
et al
. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.
Hepatology
, 2009, 49(2): 453-459.
|
16. |
18 Bouza C, López-Cuadrado T, Alcázar R,
et al
. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma.
BMC Gastroenterol
, 2009, 9(1): 31-40.
|
17. |
19 Orlando A, Leandro G, Olivo M,
et al
. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.
Am J Gastroentero
, 2009, 104(2): 514-524.
|
18. |
21 Meng MB, Cui YL, Lu Y,
et al
. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Radiother Oncol
, 2009, 92(2): 184-194.
|
19. |
25 Mornex F, Girard N, Beziat C,
et al
. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies–mature results of the French Phase II RTF-1 trial.
Int J Radiat Oncol Biol Phys
, 2006, 66(4):1152-1158.
|
20. |
26 Zhang XB, Wang JH, Yan ZP,
et al
. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization.
Cancer
, 2009, 115(6): 1245-1252.
|
21. |
27 You CR, Jang JW, Kang SH,
et al
. Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis.
Korean J Hepatol
, 2007, 13(3): 378-386.
|
22. |
28 Guo WJ, Yu EX, Liu LM,
et al
. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.
World J Gastroenterol
, 2003, 9(8): 1697-1701.
|
23. |
29 Yamada K, Izaki K, Sugimoto K,
et al
. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys
, 2003, 57(1): 113-119.
|
24. |
30 Samuel M, Chow PK, Chan Shih-Yen E,
et al
. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
Cochrane Database Syst Rev
, 2009, 1(1): CD001199.
|
25. |
31 Söderdahl G, Bäckman L, Isoniemi H,
et al
. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma.
Transpl Int
, 2006, 19(4): 288-294.
|
26. |
32 Bayraktar Y, Balkanci F, Kayhan B,
et al
. A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma.
Hepatogastroenterology
, 1996, 43(9): 681-687.
|
27. |
33 Mabed M, Esmaeel M, El-Khodary T,
et al
. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
Eur J Cancer Care (Engl)
, 2009, 18(5): 492-499.
|
28. |
34 Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T,
et al
. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma.
Hepatogastroenterology
, 1999, 46(26): 1122-1125.
|
29. |
35 Zhang T, Ding X, Wei D,
et al
. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Anticancer Drugs
, 2010, 21(3): 326-332.
|
30. |
36 Llovet JM, Rico S, Mazzaferro V,
et al
. Sorafenib in advanced hepatocellular carcinoma.
New Engl J Med
, 2008, 59(4): 378-390.
|
31. |
37 Cheng AL, Kang YK, Chenz,
et al
. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, Placebo-controlled trial.
Lancet Onto
, 2009, 10(1): 25-34.
|
32. |
38 Zhao JD, Liu J, Ren ZG,
et al
. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Radiat Oncol
, 2010, 5(1): 12-19.
|
33. |
39 Meng MB, Cui YL, Guan YS,
et al
. Traditional Chinese medicine plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.
J Altern Complement Med
, 2008, 14(8): 1027-1042.
|
34. |
40 Wu P, Dugoua JJ, Eyawo O,
et al
. Traditional Chinese Medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis.
J Exp Clin Cancer Res
, 2009, 28(1): 112-125.
|
35. |
陈晓明, 罗鹏飞, 邵培坚, 等. 肝癌节段性栓塞化疗与常规栓塞化疗的比较研究. 中华放射学杂志, 2000, 34(4): 271-273.
|
36. |
陈敏山, 李锦清, 梁惠宏, 等. 经皮射频消融与手术切除治疗小肝癌的疗效比较. 中华医学杂志, 2005, 85(2): 80-83.
|
37. |
康春博, 许洪斌, 王世龙, 等. TACE联合RFA治疗大肝癌的研究. 中华肝胆外科杂志, 2007, 13(12): 828-830.
|
38. |
马晴, 吕慧, 王燕, 等. 三维适形放疗联合肝动脉栓塞化疗治疗原发性肝癌疗效的Meta分析. 疑难病杂志, 2009, 8(12): 718-721.
|
39. |
吴莉, 文小平, 黄薇. 原发性肝癌三维适形放疗联合介入治疗的临床研究. 中华放射医学与防护杂志, 2006, 26(3): 256-258.
|
40. |
娄繁, 包永星, 牛永健. 肝动脉栓塞化疗联合三维适形放疗治疗Ⅱ期原发性肝癌疗效分析. 中华放射肿瘤学杂志, 2009, 18(6): 474-476.
|